Evidence map›Paper›PMID 31019569›Full record

ArticleTherapeutic advances in medical oncology2019

Adjuvant chemotherapy improves prognosis of resectable stage IV colorectal cancer: a comparative study using inverse probability of treatment weighting.

Hiroaki Nozawa, Hirotoshi Takiyama, Kiyoshi Hasegawa, Kazushige Kawai, Keisuke Hata, Toshiaki Tanaka, Takeshi Nishikawa, Kazuhito Sasaki, Manabu Kaneko, Koji Murono and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Photothermal therapy technology of metastatic colorectal cancer.American journal of translational research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Hiroaki NozawaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.ORCID https://orcid.org/0000-0002-7891-5986
Hirotoshi TakiyamaDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Kiyoshi HasegawaDepartment of Hepatobiliary and Pancreatic Surgery, The University of Tokyo, Tokyo, Japan.
Kazushige KawaiDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Keisuke HataDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Toshiaki TanakaDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Takeshi NishikawaDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Kazuhito SasakiDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Manabu KanekoDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Koji MuronoDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Shigenobu EmotoDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Hirofumi SonodaDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Jun NakajimaDepartment of Thoracic Surgery, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdjuvant chemotherapy (AC) is known to be beneficial for stage III colorectal cancer (CRC). In contrast, only a few studies have reported the survival benefits of AC for stage IV CRC after curative surgery.

methodsWe identified 155 CRC patients with various organ metastases who underwent curative surgery in our hospital between 2003 and 2017. Clinicopathological parameters and postoperative AC were reviewed. Multivariate analyses were performed to identify prognostic factors. Moreover, the effects of AC on recurrence-free survival (RFS) and overall survival (OS) were analyzed using inverse probability of treatment weighting.

resultsThe cohort comprised 94 males and 61 females, with a mean age of 63 years. AC was administered to 57% of patients who underwent surgery between 2003 and 2010 and 76% between 2011 and 2017 (

conclusionAC can be discussed with resectable stage IV CRC patients because of its significant survival-improving effects.

Indexed as

adjuvant chemotherapycolorectal cancerinverse probability of treatment weightingprognosisregional lymph node metastasesstage IV

Identifiers

PMID31019569
PMCPMC6469283
OpenAlexW2937173699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.